High-Risk Localized Renal-Cell Carcinoma May Benefit from Neoadjuvant Combination of Avelumab and Axitinib

Press/Media

Period	Sep 15 2022

Media coverage

Title	High-Risk Localized Renal-Cell Carcinoma May Benefit from Neoadjuvant Combination of Avelumab and Axitinib
Media name/outlet	Oncology Pharmacist.com
Country/Territory	United States
Date	09/15/22
URL	https://theoncologypharmacist.com:443/top-issues/2022-issues/september-2022-vol-15-no-5/19188-high-risk-localized-renal-cell-carcinoma-may-benefit-from-neoadjuvant-combination-of-avelumab-and-axitinib
Persons	Daniel Geynisman